LDN 193189 hydrochloride
- Product Name
- LDN 193189 hydrochloride
- CAS No.
- 1435934-00-1
- Chemical Name
- LDN 193189 hydrochloride
- Synonyms
- DM-3189 2HCl;LDN-193189 2HC;LDN-193189 2HCl;LDN-193189 (DM3189) 2HCl;LDN 193189 dihydrochloride;Viomycin LDN 193189 Dihydrochloride;4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline dihydrochloride
- CBNumber
- CB03146321
- Molecular Formula
- C25H24Cl2N6
- Formula Weight
- 479.40426
- MOL File
- 1435934-00-1.mol
LDN 193189 hydrochloride Property
- storage temp.
- -20°C
- solubility
- Soluble in DMSO or in Water (up to 5 mg/ml)
- form
- solid
- color
- Orange-yellow
- Stability:
- Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 2 months.
N-Bromosuccinimide Price
- Product number
- 19396
- Product name
- LDN-193189 (hydrochloride)
- Packaging
- 5mg
- Price
- $56
- Updated
- 2024/03/01
- Product number
- 19396
- Product name
- LDN-193189 (hydrochloride)
- Packaging
- 25mg
- Price
- $219
- Updated
- 2024/03/01
- Product number
- 19396
- Product name
- LDN-193189 (hydrochloride)
- Packaging
- 1mg
- Price
- $25
- Updated
- 2024/03/01
- Product number
- 19396
- Product name
- LDN-193189 (hydrochloride)
- Packaging
- 10mg
- Price
- $100
- Updated
- 2024/03/01
- Product number
- 6053
- Product name
- LDN193189dihydrochloride
- Purity
- ≥98%(HPLC)
- Packaging
- 10
- Price
- $216
- Updated
- 2021/12/16
LDN 193189 hydrochloride Chemical Properties,Usage,Production
Description
LDN-193189 inhibits SMAD1/5/8 phosphorylation by the bone morphogenetic protein (BMP) type I receptors, which are known as activin receptor-like kinases (ALKs), with an IC50 value of 4.9 nM. In in vitro kinase assays, it shows specificity for ALK1, 2, 3, and 6 (IC50s = 0.8, 0.8, 5.3, and 16.7 nM, respectively) over ALK4 and 5 (IC50s = 101 and 350 nM, respectively). LDN-193189 has been used to inhibit BMP type I receptor activity to study the pathogenesis of fibrodysplasia ossificans progressive, a congenital hyperossification disorder, and to examine the role of osteogenesis in prostate tumor metastases in bone.
storage
-20°C
References
1) Yu?et al.?(2008),?BMP type 1 receptor inhibition reduces heterotropic ossification; Nature Med.,14?1363 2) Chambers?et al.?(2012),?Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors; Nature Biotechnol.?30?715 3) Kreitzer?et al. (2013)?A robust method to derive functional neural crest cells from human pluripotent stem cells; Am. J. Stem Cells,?2?119 4) Lee?et al.?(2011)?BMP4 promotes prostate tumor growth in bone through osteogenesis; Cancer Res.?71?5194